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Background: Chronic metabolic overload leads to insulin resistance in a variety of tissues. It has been shown that
exposure to saturated fatty acid palmitate can cause insulin resistance in skeletal muscle cells. Fatty acid induced
synthesis of ceramide is considered to be one of the major causes for insulin resistance. Both de novo synthesis and
sphingomyelin hydrolysis by sphingomyelinase are implicated for ceramide generation. Aim of this study was to
evaluate the impact of neutral sphingomyelinase (nSMase) inhibition on saturated fatty acid induced lipotoxicity
and insulin resistance in skeletal muscle myotubes.
Results: Treatment of saturated fatty acid (palmitate) but not unsaturated fatty acid (oleate) caused an up-regulation in
expression of various nSMase genes which are associated with ceramide synthesis through the salvage pathway.
Inhibition of nSMase by a pharmacological inhibitor (GW4869) partially reverted the palmitate induced insulin
resistance in C2C12 myotubes. Inhibition of nSMase improved metabolic functions of myotubes as measured by
improved oxidative capacity in terms of increased mitochondrial number, PGC1α expression and ATP levels with
concomitant decrease in intramyocellular triglyceride levels. Palmitate induced inflammatory response was also
reduced by nSMase inhibitor. GW4869 treatment reduced palmitate induced oxidative and endoplasmic reticulum
stress and improved cell survival.
Conclusion: In this study, we provide evidences that inhibition of nSMase can protect skeletal muscles from
saturated fatty acid induced insulin resistance, metabolic dysfunction, cellular stress and inflammation.
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T2DMBackground
Insulin resistance is a central phenomenon under meta-
bolic disorders such as type 2 diabetes mellitus (T2DM).
Understanding the defects in metabolism and underlying
regulatory molecular network is of importance to design
an effective therapy to manage T2DM and peripheral in-
sulin resistance. Dealing with insulin resistance in skel-
etal muscle is of prime importance because this tissue
accounts for as high as 95% glucose disposal during
hyperglycemic hyperinsulinemic condition (Baron et al.* Correspondence: m.r.jagannath@connexios.com
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in any medium, provided the original work is p1988) and it is the major site for energy expenditure
(van der Vusse and Reneman 1996).
Skeletal muscles from diabetic patients show impaired
glucose uptake, storage and utilization because of dimin-
ished insulin signaling (Kelley et al. 1996; Kim et al.
1999; Krook et al. 2000; Bouzakri et al. 2003). Insulin re-
sistance mediated defects are not limited only to glucose
metabolism instead can influence several aspects of me-
tabolism like overall reduction in the oxidative capacity
as evident by the number/activity of mitochondria and
reduced ATP levels (Simoneau and Kelley 1997; Kelley
et al. 2002; Scheuermann-Freestone et al. 2003; Schrauwen
and Hesselink 2004; Asmann et al. 2006; Szendroedi et al.n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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creased oxidative and endoplasmic reticulum (ER) stress
and chronic low grade inflammation (Hey-Mogensen
et al. 2010).
One of the major factors causing insulin resistance is
elevated plasma free fatty acids (FFA) levels (Itani et al.
2002). In fact, increased rate of lipolysis from adipose
tissue and VLDL secretion from liver are observed in
T2DM patients and both of these might contribute for
muscle FA overload. Further, augmentation in muscle fat
storage is contributed by raised plasma FFA level, in-
creased fat uptake (Bonen et al. 2004), and defective or in-
complete oxidation in skeletal muscle of diabetic patients
(Mootha et al. 2003; Patti et al. 2003; Mensink et al. 2007;
Mogensen et al. 2007; Koves et al. 2008). Fatty acid over-
load leads to its accumulation in skeletal muscle mainly
in form of diacylglycerol (DAG), triglyceride (TG) or
ceramide in obese and T2DM patients (Goodpaster
et al. 2000; Bonen et al. 2004). Increased fat storage in
form of TG can be directly correlated to insulin resist-
ance in the sedentary subjects (McGarry 2002) but not
in the exercise trained ones (Goodpaster et al. 2001).
On the other hand, storage of fat in terms of neutral TG
might be a protective mechanism (Listenberger et al.
2003). This hypothesis is strengthened by studies which
showed that unsaturated fatty acid oleate, which is a
preferred substrate for TG synthesis, did not demonstrate
toxic impacts (Listenberger et al. 2003; Yuzefovych et al.
2010). These evidences lead to the speculation that lipid
metabolism in the form other than TG storage is required
for development of insulin resistance.
Metabolism of lipid into complex lipid such as ceramide
is reported to develop insulin resistance. Ceramide levels
in cells are controlled by de novo synthesis or by its gener-
ation through salvage pathway using sphingomyelinase
(SMase). The enzyme serine palmitoyl transferase (SPT)
catalyzes the rate limiting step for de novo sphingolipid
synthesis. Its expression and activity are increased in
T2DM, insulin resistant subjects, and in response to satu-
rated fatty acid and inflammatory cytokines. A number of
studies indicated that pharmalogical inhibition of SPT can
protect from insulin resistance and lipotoxicity (Holland
et al. 2007; Ussher et al. 2010). The de novo synthesis of
ceramides is triggered primarily from saturated fatty
acids, which are one of the major contributors for insu-
lin resistance, under various conditions relevant to
metabolic syndrome such as lipotoxicity, inflammation,
glucocorticoids (Holland et al. 2007; Zierath 2007;
Blachnio-Zabielska et al. 2010). Treatment of cells with
ceramide itself can cause insulin resistance (Schmitz-
Peiffer et al. 1999; Pickersgill et al. 2007). Increased cer-
amide levels lead to inflammation, ER stress, oxidative
stress and apoptosis (Turpin et al. 2006; de Mello et al.
2009). In obese T2DM patients, increased ceramidelevel is observed in plasma (Haus et al. 2009), liver
(Boon et al. 2013), adipose (Blachnio-Zabielska et al. 2012)
and skeletal muscle (Adams et al. 2004). Moreover, skel-
etal muscle ceramide levels are found to be increased in
subjects at risk of development of T2DM (Straczkowski
et al. 2007). In fact, there exists a positive correlation
between ceramide concentration and degree of insulin
resistance (Straczkowski et al. 2004, 2007; Turpin et al.
2006; Haus et al. 2009; Blachnio-Zabielska et al. 2012).
Therefore, it was inferred that fatty acid overload in-
duced lipotoxicity and insulin resistance are mediated,
at least in part, by synthesis of ceramide from saturated
fatty acids while inhibition of ceramide synthesis could
protect both cultured cells (Schmitz-Peiffer et al. 1999;
Turpin et al. 2006; Pickersgill et al. 2007) and rodent
model of disease (Holland et al. 2007; Yang et al. 2009;
Ussher et al. 2010).
Ceramide and sphingomyelin are interconverted by
enzymes sphingomyeline synthase (SMS) and sphingo-
myelinase (SMase). Sphingomyelin to ceramide ratio is
inversely correlated to neutral SMase (nSMase) level in-
dicating important role of nSMase in maintaining levels
of these sphingolipids (Dobrzyń et al. 2002). Inflamma-
tory cytokines can increase nSMase activity thereby in-
creasing ceramide levels (Long and Pekala 1996). Level
of nSMase is found to be increased in impaired glucose
tolerant subjects (Straczkowski et al. 2007) and high fat
diet induced diabetic rodents (Murase et al. 1998; Shah
et al. 2008). Recent review from our laboratory exploring
the gene expression profiles revealed that in T2DM pa-
tients the levels of sphingomyelinase are up-regulated
(Pralhada Rao et al. 2013). Conversely, level of nSMase
is decreased after exercise (Dobrzyń et al. 2002; Helge
et al. 2004) leading to an increase in sphingomyelin to cer-
amide ratio. These reports suggest that targeting nSMase
can reduce ceramide level thereby making tissue insulin
sensitive. Despite these indications, there is no substantial
data available in literature which can demonstrate the role
of nSMase for skeletal muscle insulin resistance.
Here we report that inhibition of membrane localized
neutral sphingomyelinase by a small molecule inhibitor
can protect C2C12 skeletal muscle myotubes from
palmitate induced insulin resistance. We demonstrate
that nSMase expression is increased during palmitate
treatment but not during oleate treatment. Inhibition of
nSMase improves myotubes oxidative capacity and re-
duces triglyceride storage. Its inhibition also reduces
cellular stress, inflammation and improves cell survival.
Therefore, we conclude that nSMase inhibition can pro-
tect skeletal muscle from saturated FFA overload in-
duced lipotoxic impacts. Hence, we believe that this
strategy hold promise to provide opportunity for thera-
peutic interventions to treat muscle pathology present
in metabolic syndrome.
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Palmitate treatment increases nSMase expression in
C2C12 myotubes
Following palmitate (750 μM) or oleate (750 μM) treat-
ment to differentiated myotubes for 16 hrs, we mea-
sured expression of nSMase genes isoforms. Expression
of nSMase-1 was up-regulated by 1.38 fold under palmi-
tate treatment (P < 0.01, Figure 1A) when compared to
vehicle control set. An increase in nSMase-2 expression
was also observed under palmitate condition (1.85 fold
of vehicle control, P < 0.05, Figure 1B) whereas nSMase-3
expression was slightly increased (1.29 fold of vehicle
control, P < 0.05, Figure 1C). Oleate treatment was unable
to induce the expression of nSMaes (Figure 1A, B, C).
These results indicate an increase in nSMase expression
after exposure to saturated FFA.
We next measured the expression of SPT (SPTLC1),
a rate limiting enzyme in the de novo pathway of cer-
amide biosynthesis. Similar to an increase in nSMase
expression, SPTLC1 expression was also up-regulated
under palmitate treatment (1.22 fold of vehicle control,
P < 0.05) but not under oleate treatment (Figure 1D).
Thus palmitate treatment can increase both de novo
and nSMase mediated ceramide synthesis pathways in-
dicating a potential increase in ceramide synthesis.
However, we did not measure total ceramide levels in
the cells but studied functional outcomes as mentioned
henceforth.Figure 1 Palmitate treatment increases nSMases expression. Differenti
or oleate (750 μM) for 16 hrs as described under ‘Methods’ section. After tr
nSMase-2 (B), nSMase-3 (C) and SPTLC1 (D) were quantified by quantitativ
presented as mean + standard deviation. n = 4, **P < 0.01, *P < 0.05, one wa
analyses.Inhibition of nSMase reduces palmitate induced insulin
resistance in C2C12 myotubes
We hypothesized that nSMase inhibition can reduce
skeletal muscle insulin resistance caused by palmitate
overload. C2C12 myotubes were treated with palmitate
in presence or absence of nSMase inhibitor, GW4869
(10 μM) for 16 hrs. After 16 hrs, myotubes were treated
with or without insulin for 10 min and insulin sensitivity
was assessed by phosphorylated Akt. As seen in Figure 2A,
insulin treatment could increase Akt phosphorylation in
myotubes treated with vehicle control (P < 0.001). Palmi-
tate treatment showed reduced Akt phosphorylation in re-
sponse to insulin (P < 0.01) hence indicated development
of insulin resistance. Inhibition of nSMase with palmitate
treatment maintained Akt phosphorylation (P < 0.01) and
thus improved insulin sensitivity (Figure 2A).
We next studied insulin induced changes in PDK4
expression, a gene whose expression level is negatively
regulated with glucose oxidation. The levels of PDK4
are known to reduce with insulin treatment. Expres-
sion of PDK4 was up-regulated by palmitate exposure
(Figure 2B). Insulin treatment could reduce its expres-
sion only in vehicle treated cells (0.75 fold, P < 0.01)
but not in palmitate treated cells thus demonstrating
progression of insulin resistance (Figure 2B). Inhibition
of nSMase in this condition maintained insulin sensitivity
of skeletal muscle cells as insulin was able to inhibit PDK4
expression (P < 0.01, Figure 2B). Hence we conclude thatated C2C12 myotubes were treated with vehicle control or palmitate
eatments, total RNA was isolated and mRNA levels of nSMase-1 (A),
e real time PCR using β-actin as housekeeping gene control. Data are
y ANOVA with Newman-Keuls post test was performed for statistical
Figure 2 Palmitate induced insulin resistance is alleviated by nSMase inhibition. (A) After palmitate treatment, C2C12 myotubes were
starved for 30 min. Myotubes were then treated with or without insulin for 10 min followed by lysing in lysis buffer. Insulin induced Akt
phosphorylation was measured in total cell lysate by Western blotting. Unphosphorylated levels of Akt were also measured as control for
phosphorylation (Upper panel). Lower panel: quantification of Akt phosphorylation (n = 6, ***P < 0.001, **P < 0.01) (B) C2C12 cells were treated
with or without palmitate for 2 hrs in presence or absence of nSMase inhibitor (GW4869). Insulin was also present in the treatments for indicated
sets. Gene expression level of PDK4 was analyzed by quantitative real time PCR using β-actin as housekeeping gene control. Data are presented
as mean + standard deviation. n = 4, **P < 0.01, *P < 0.05, ns: not significant, one way ANOVA with Newman-Keuls post test was performed for
statistical analyses.
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induced insulin resistance. Oleate treatment increased
PDK4 expression in C2C12 cells, it did not cause severe
insulin resistance as insulin treatment was able to inhibit
its expression (P < 0.01, Additional file 1). Inhibition of
nSMase maintained insulin sensitivity of oleate treated
cells.
Inhibition of nSMase results in improved oxidative
capacity and metabolism
Since insulin resistance is associated with impaired metab-
olism, we asked whether nSMase inhibition can improve
metabolic functions of skeletal muscles. We measured im-
pact of nSMase inhibition on expression of PGC1α, a gene
which is implicated for mitochondrial biogenesis, fat oxi-
dation and energy metabolism. Exposure of palmitate re-
duced PGC1α expression to 0.47 fold when compared to
vehicle control (P < 0.01, Figure 3A). Inhibition of nSMase
in this background increased PGC1α expression by 30%
(P < 0.05, Figure 3A). Mitochondrial DNA copy number, a
surrogate measurement for mitochondria number, was re-
duced by palmitate treatment (0.39 fold of vehicle control,
P < 0.05) and nSMase inhibition could restore the mito-
chondrial number (P < 0.05, Figure 3B). In consistence
with this, cellular ATP levels were found to be reduced
under palmitate treatment (0.41 nano-moles/mg versus
0.72 nano-moles/mg under vehicle control, P < 0.01) and
nSMase inhibitor increased its level by 35% (0.56 nano-Figure 3 Inhibition of nSMase improves oxidative capacity of C2C12 m
expression in C2C12 myotubes cultured under palmitate condition in prese
housekeeping gene control. (B) Mitochondrial DNA copy numbers were es
myotubes cultured under control or palmitate condition in presence or ab
were quantified by assessing ND1 (mitochondrial gene) level which was no
(D) were quantified after culturing C2C12 myotubes under similar conditions
standard deviation. n = 4, ***P < 0.001, **P < 0.01, *P < 0.05, one way ANOVA wmoles/mg, P < 0.05, Figure 3C). Taken together, nSMase
inhibition improved oxidative capacity of skeletal muscle
myotubes.
We reasoned that improved insulin sensitivity and
oxidative capacity by nSMase inhibition would impact fat
storage. Under palmitate treatment, triglyceride storage
was enhanced by 3.65 fold (50 μg/mg versus 14 μg/mg
under vehicle control, P < 0.001, Figure 3D). Inhibition of
nSMase under palmitate treatment led to a partial reduc-
tion in cellular triglyceride storage (41 μg/mg, P < 0.01,
Figure 3C). Hence, nSMase inhibition improves overall
metabolic function of skeletal muscle.
Neutral SMase inhibition reduces inflammation and
cellular stress
We next examined the impact of nSMase inhibition on
cellular health. Palmitate treatment enhanced JNK
phosphorylation (2.02 fold of control, P < 0.05) and NFκB
activation as measured by reduction in IκB levels (0.44
fold of vehicle control, P < 0.01, Figure 4A) thus indicating
enhanced stress signaling. Inhibition of nSMase under
this background reduced stress signaling as evident by
reduced JNK phosphorylation (1.07 fold of vehicle
control, P < 0.01) and restoration of IκB levels (0.90
fold, P < 0.01, Figure 4A). In consistence with these data,
palmitate induced increase in the IL6 expression (16 fold
of control, P < 0.001) was partially decreased by nSMase
inhibition (P < 0.001, Figure 4B). Treatment of myotubesyotubes and reduces TG storage. (A) Analysis of PGC1α gene
nce or absence of nSMase inhibitor (GW4869). β-actin was used as
timated by quantitative real time PCR using total DNA isolated from
sence of nSMase inhibitor (GW4869). Mitochondrial DNA copy number
rmalized to HPRT (nuclear gene). Cellular ATP levels (C) and TG storage
as described under ‘Methods’ section. Data are presented as mean +
ith Newman-Keuls post test was performed for statistical analyses.
Figure 4 (See legend on next page.)
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Figure 4 Reduction in stress signaling, inflammation, oxidative stress and ER stress by nSMase inhibition. (A) After palmitate treatment
in presence or absence of nSMase inhibitor (GW4869), C2C12 myotubes were harvested in lysis buffer. Upper panel: Levels of phosphorylated
JNK, unphosphorylated JNK, IκB, BiP and CHOP were measured using Western blotting. β-actin was used as a loading control. Lower panels:
quantification of Western blotting data. (B) Gene expression of IL6 was measured by quantitative real time PCR using β-actin as housekeeping
gene control. (C) After treatment, myotubes were loaded with DCFH-DA ROS indicator fluorescent probe to quantify the amount of cellular ROS.
(D) Nitric oxide levels in culture medium were quantified using Griess reagent. (E) Myotubes viability was measured by MTT assay after treatment.
Data are presented as mean + standard deviation. n = 4, ***P < 0.001, **P < 0.01, *P < 0.05, one way ANOVA with Newman-Keuls post test was
performed for statistical analyses.
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IL6 expression and inhibition of nSMase did not change
it further (Additional file 2). Thus, nSMase inhibition
can reduce palmitate induced stress signaling and
inflammation.
Palmitate treatment resulted in enhanced BiP (3.4 fold
of control, P < 0.001) and CHOP (4 fold of control, P <
0.01) levels demonstrating increased ER stress (Figure 4A).
Inhibition of nSMase reduced ER stress as measured by
partial reduction in the levels of BiP and CHOP (P < 0.01,
Figure 4A). Similarly, palmitate treatment elevated oxida-
tive stress as levels of both reactive oxygen species (ROS)
and reactive nitrite species (RNS) were found to be in-
creased (Figure 4C, D). Both ROS and RNS levels were
significantly reduced by nSMase inhibition (Figure 4C, D).
Both ROS and RNS levels were unchanged under oleate
treatment and nSMase inhibition did not show any effect
under oleate (Additional file 2). Hence, palmitate induced
both oxidative and ER stress are reduced by nSMase
inhibitor.
Next, we analyzed the impact of palmitate treatment
on myotubes survival. Palmitate treatment reduced cell
survival as measured by MTT assay (70% of vehicle
control, P < 0.001, Figure 4E). However, oleate treat-
ment did not reduce cell survival (Additional file 2).
Inhibition of nSMase under palmitate condition pro-
tected myotubes survival (84% of control, P < 0.001,
Figure 4E). Taken together, nSMase inhibition reduces
cellular stress and enhances cell survival under palmi-
tate treatment.
Discussion
Lipid mediators are important signaling molecules for
tissue homeostasis. Ceramides are potent lipid signaling
molecules and act as metabolic hub because many other
sphingolipids are derived from it (Scheffer et al. 2011;
Pralhada Rao et al. 2013). Ceramide biology is becoming
increasingly important because ceramide can impair
activation of insulin signaling pathway and hence any
modulation in its content can lead to better insulin
sensitivity. In fact, a direct correlation exists between
the concentration of saturated fatty acid present and
the amount of ceramide generated (Adams et al. 2004).
Also there is a direct correlation between amount ofceramide and degree of insulin resistance (Straczkowski
et al. 2004, 2007; Turpin et al. 2006; Haus et al. 2009;
Blachnio-Zabielska et al. 2012). Therefore, it is believed
that generation of ceramide in response to FFA overload
is one of the most important events causing insulin
resistance (Schmitz-Peiffer et al. 1999).
FFA exposure initiates de novo synthesis of sphingolipids
and concomitantly ceramide levels are also increased
(Schmitz-Peiffer et al. 1999, Hu et al. 2009). Consequently,
a number of groups tried to inhibit de novo synthesis of
sphingolipids and reported better insulin sensitivity
(Chavez et al. 2003; Powell et al. 2004; Holland et al.
2007; Watson et al. 2009; Ussher et al. 2010). However,
it should be noted that not all species of sphingolipids
can prompt insulin resistance. In fact, generation of
sphingosine-1-phosphate (S1P) by sphingosine kinase
(Hu et al. 2009) can ameliorate insulin resistance. S1P
can increase glucose uptake in skeletal muscle cells
(Rapizzi et al. 2009). Over-expression of sphingosine
kinase to generate S1P or administration of S1P analog,
FTY720, protect animal model of diabetes from insulin
resistance (Kendall and Hupfeld 2008; Bruce et al. 2012,
2013). Moreover, conversion of ceramide to sphingosine
by ceramidase hence providing substrate for S1P gener-
ation exerts negative correlation with FFA induced insulin
resistance (Chavez et al. 2003, 2005). Hence, we sought to
inhibit ceramide generation from sphingomyelin hydroly-
sis though the action of enzyme SMases which is found to
be up-regulated during glucose intolerance (Murase et al.
1998; Straczkowski et al. 2007; Shah et al. 2008).
We exposed differentiated C2C12 myotubes for 16 hrs
to saturated FFA palmitate which is known to increase
cellular ceramide contents (Schmitz-Peiffer et al. 1999).
To inhibit nSMases, we used a small molecule inhibitor,
GW4869, which is reported to reduce ceramide levels
(Luberto et al. 2002). Though we ourselves did not
measure the total ceramide content, we observed an in-
crease in expression of genes involved in ceramide syn-
thesis upon palmitate treatment and estimated the
functional outcomes after intervention in the ceramide
synthesis pathway. To examine the relationship between
nSMase and insulin resistance, we first demonstrated
that the levels of all three nSMases were increased under
palmitate with attendant decrease in insulin stimulated
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agreement with what is observed in diabetic patients.
Treatment with oleate did not increase the nSMases
expression and it is reported that this fatty acid does not
increase the ceramide content of the cells. Inhibition of
nSMases, as expected, maintained insulin stimulated Akt
phosphorylation indicating improved insulin sensitivity.
Our data show that under nSMase inhibition, PDK4 ex-
pression was increased by palmitate and was decreased
by insulin thus suggesting that metabolic flexibility of
myotubes is maintained. PDK4 is a negative regulator of
glucose oxidation which inhibits pyruvate entry into
mitochondria for further oxidation while fat oxidation is
promoted. Metabolic flexibility or ability to switch fuel
utilization from fat to glucose is lost during insulin re-
sistance since PDK4 levels are elevated (Kim et al. 2006,
Tsintzas et al. 2007; Kulkarni et al. 2012). Insulin in-
duced increase in Akt phosphorylation and decrease in
PDK4 expression in myotubes cultured under nSMase
inhibitor suggest functional insulin signaling cascade.
While a number of reports have authenticated connec-
tion between ceramide content and insulin resistant, we
extended the study to see the effects on oxidative capacity
given that overall oxidation is severely impaired in human
patients (He et al. 2001; Oberbach et al. 2006; Koves et al.
2008). In order to study the impact on oxidative capacity
we measured expression of PGC1α - master regulator of
mitochondrial biogenesis and oxidative capacity, mito-
chondrial number and ATP levels. All these indicators of
oxidative capacity were reduced under palmitate whereas
nSMase inhibition could significantly restore their levels.
Improvement in oxidative capacity by nSMase inhibition
also resulted in moderate but statistically significant re-
duction in TG storage. Only partial restoration in oxi-
dative capacity and reduction in TG storage by nSMase
inhibition might be a result of defects caused by satu-
rated FFA other than ceramide synthesis or contribu-
tion of de novo ceramide biosynthesis as we observed
an increase in expression of SPT, a rate limiting enzyme
of this pathway.
Both saturated FFA and ceramide activate JNK and
NFκB signaling which can lead to cellular stress (Itani
et al. 2002; Yuzefovych et al. 2010; MohammadTaghvaei
et al. 2012). Therefore we examined JNK and NFκB
activation, oxidative and ER stress and generation of
inflammatory cytokines. Consistent with the data on
oxidative capacity, nSMase inhibition only partially re-
duced cellular stress and IL6 expression again indicat-
ing about role of FFA other than ceramide synthesis
for cellular stress or contribution of de novo ceramide
biosynthesis. Importance of de novo ceramide biosyn-
thesis in this regard is already reported. One possible
explanation about the role of FFA other than ceramide
synthesis is that extracellular FFA can directly activatetoll like receptors (TLRs) which downstream activate
JNK and NFκB (Senn 2006). JNK and NFκB activation
results in inflammatory cytokines production and ele-
vation of cellular stress which itself can impair oxida-
tive capacity and insulin signaling.
Overall our data establish, for the first time, the role of
nSMase in protecting skeletal muscle from saturated
FFA induced lipotoxic impacts while maintaining insulin
sensitivity.
Conclusions
In this study, we report that inhibition of nSMase can
prevent saturated FFA overload induced insulin resistance
and multiple defects in metabolism. Inhibition of nSMase
can also reduce palmitate induced stress and inflamma-
tion. Palmitate but not oleate treatment up-regulates ex-
pression of all three nSMases which generate ceramide
from sphingomyelin. Palmitate treatment led to insulin re-
sistance as well as to reduced oxidative capacity. Exposure
of myotubes to palmitate caused oxidative stress, ER
stress, stress signaling, inflammatory cytokine produc-
tion and reduced myotubes survival. We show that
these deleterious impacts of palmitate are largely by
increased nSMase levels as inhibition of nSMase could
revert these impacts (Figure 5). Hence, inhibition of
nSMase can be a good approach to reduce skeletal
muscle insulin resistance and defects in metabolism.
Methods
Cell culture and palmitate treatment
C2C12 myoblast cell line (ATCC) was maintained in
undifferentiated state at low confluency in DMEM (Sigma)
containing 25 mM glucose, 10% fetal bovine serum
(Invitrogen), penicillin and streptomycin. Myoblasts were
differentiated into myotubes in multi-well plates after
growing till complete confluency in growth medium and
followed by culturing in reduced serum (2%) medium for
four days with media change at every alternate day. Fully
differentiated cells evident by long multi-nucleated
myotubes were used for the experiments.
Palmitate or oleate (Sigma) were dissolved in 50%
ethanol followed by conjugation with 10% BSA. Differ-
entiated myotubes received BSA conjugated palmitate or
oleate (5 mM) to a final concentration of 750 μM and
were cultured for 16 hrs. Vehicle control treatment in-
cluded equal amount of BSA and ethanol for 16 hrs. For
inhibition of nSMases, GW4869 (Sigma) was also added
to a final concentration of 10 μM along with palmitate
or oleate for 16 hrs.
Analysis of gene expression
Differentiated myotubes were cultured with indicated
treatment for 16 hrs. After 16 hrs of treatment, total
RNA was extracted using Trizol reagent (Invitrogen) and
Figure 5 Saturated FFA mediated impairment in skeletal muscle and its reversal by nSMase inhibition. Sphingomyelin can be converted
into ceramide by nSMases. Palmitate mediated up-regulation of nSMases can expedite this process of ceramide generation. Increased ceramide
can lead to an inhibition on insulin signaling pathway thereby reducing glucose oxidation. In this condition PGC1α levels are reduced with a
concomitant decrease in muscle oxidative capacity. Because of impaired oxidative function and palmitate overload, fat storage in form of TG is
increased. Palmitate overload mediated increased ceramide levels elevate cellular oxidative stress, ER stress and inflammation which can severely
affect cell survival. Elevated stress and inflammation can directly inhibit insulin signaling and can impair oxidative capacity (represented as dashed
arrows). Palmitate mediated impact on cellular responses is represented by a thick up or down arrow placed just after particular cellular response.
Inhibition of nSMase under this background reverses palmitate mediated impact on cellular response.
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dom hexamer primers (Applied Biosystems). A total of 5
ng of cDNA was used for real time PCR for quantification
of gene expression using SYBR Green PCR Master Mix
(Eurogenetic). Genes analyzed in this study were nSMase-
1, nSMase-2, nSMase-3, SPTLC1, PDK4, PGC1α and IL6.
β-actin was used as a housekeeping gene control.
For PDK4 (pyruvate dehydrogenase kinase 4) expres-
sion, C2C12 cells were cultured for 2 hrs in presence or
absence of vehicle, palmitate (750 μM), oleate (750 μM),
GW4869 (10 μM) or insulin (100 nM). Cells were then
harvested for gene expression analysis.Western blotting
After treatment myotubes were lysed and amounts of
total proteins were estimated using Bradford reagent
(Bio-Rad). Equal amount of protein (30 μg) was resolved
by SDS-PAGE and then transferred to nitrocellulose
membrane and signals were developed by chemilumin-
escence. Primary antibodies used were phospho-Akt, Akt,
phospho-JNK, JNK, BiP, CHOP, β-actin (Cell Signaling
Technology) and IκB (Abcam).For the estimation of insulin sensitivity by Akt phos-
phorylation, myotubes were cultured under vehicle con-
trol or palmitate treatment in the presence or absence of
GW4869 and then incubated in serum and glucose free
medium for 30 min. Subsequently, the myotubes were
treated with insulin (100 nM) for 10 min and were then
harvested for western blotting.
Western blot bands were quantified by densitometric
analysis using Image-J software (NIH).Estimation of mitochondrial DNA copy number
Post 16 hrs of culture under indicated conditions, total
DNA was isolated from myotubes. This total DNA (5 ng)
was used for quantitative real time PCR using a primer
pair specific to mitochondrial DNA (ND1) and a primer
pair specific to nuclear DNA (HPRT). Mitochondrial
DNA copy number was normalized to nuclear DNA.Estimation of cellular ATP levels
After 16 hrs of culture, myotubes were harvested for es-
timation of cellular ATP content using commercially
available kit (ATP determination kit, Invitrogen) as per
Verma et al. SpringerPlus 2014, 3:255 Page 10 of 12
http://www.springerplus.com/content/3/1/255manufacturer’s protocol. Amount of ATP was normalized
to total cellular protein.Estimation of triglyceride levels
After culture, myotubes were lysed and clear lysate was
used for TG estimation using a commercially available kit
(DiaSys). TG levels were normalized to cellular proteins
measured using Bradford reagent (Bio-Rad).Estimation of ROS
After treatments for 16 hrs, myotubes were loaded with
DCFH-DA dye (Invitrogen) for 1 h to measure ROS
levels. Amount of ROS was normalized to total cellular
DNA which was measured using bis-benzamide (Sigma).
Bis-benzamide was added for 15 min. Myotubes were
lysed and lysates were transferred to 96-well black well
plate. DCF fluorescence was measured at 485 nm exci-
tation and 528 nm emission. DNA levels were measured
at 360 nm excitation and 460 nm emission. Data are
represented as ROS fluorescence (RFU)/DNA fluores-
cence (RFU).Estimation of nitric oxide release
Nitric oxide release was measured in cell culture medium.
After treatment, culture medium was centrifuged to re-
move any debris. Culture medium was mixed with equal
amount of Griess reagent (Sigma) and incubated for
15 min followed by absorption measurement at 540 nm.
Amount of nitric oxide release was quantified by a
standard curve prepared using sodium nitrite and were
normalized to total cellular proteins measured using
Bradford reagent (Bio-Rad).MTT assay
After treatment, MTT dye was added to myotubes and
incubated for 3h. After incubation culture medium was
discarded and DMSO was added to each well to dis-
solve the reduced form of MTT (formazan). Amount of
MTT reduced was estimated by 560 nm absorbance
after correction with 640 nm absorbance. Reduction of
MTT into formazan was represented as % of vehicle
control.Statistical analysis
Data are represented as mean with standard deviation or
mean with standard error of mean. Statistical significances
were calculated by one way ANOVA with Newman-Keuls
post test using GraphPad Prism. P-values were calculated
between groups as indicated in figures and were repre-
sented as *P < 0.05, **P < 0.01 and ***P < 0.001.Additional files
Additional file 1: Impact of oleate treatment, nSMase inhibition
and insulin on PDK4 expression. C2C12 cells were treated with or
without oleate for 2 hrs in presence or absence of nSMase inhibitor
(GW4869). Insulin was also present in the treatments for indicated sets.
Gene expression level of PDK4 was analyzed by quantitative real time
PCR using β-actin as housekeeping gene control. In vehicle control
treated cells, insulin significantly inhibited PDK4 expression. Though
oleate treatment increased the PDK4 expression, it did not cause insulin
resistance as insulin was able to reduce the expression of PDK4. Inhibition
of nSMase by GW4869 maintained the insulin sensitivity of C2C12 cells.
Data are presented as mean + standard deviation. n = 4, **P < 0.01,
*P < 0.05, one way ANOVA with Newman-Keuls post test was performed
for statistical analyses.
Additional file 2: Oleate treatment does not show any impact on
inflammation, oxidative stress and cell survival. Myotubes were
treated for 16 hrs either with vehicle control or with oleate (750 μM) in
presence or absence of GW4869. Gene expression of IL6 was measured
by quantitative real time PCR using β-actin as housekeeping gene control
(A). After treatment, myotubes were loaded with DCFH-DA ROS indicator
fluorescent probe to quantify the amount of cellular ROS (B) and nitric
oxide levels in culture medium were quantified using Griess reagent (C).
Myotubes viability was measured by MTT assay (D). Data are presented as
mean + standard deviation. n = 4, one way ANOVA with Newman-Keuls
post test was performed for statistical analyses and no statistical significance
was observed among treatments indicating oleate treatment did not cause
inflammation and cellular stress and did not impact viability.
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